• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

by | Feb 14, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Unexpected Support in Tough Times With Multiple Myeloma

by | Feb 11, 2025 | Uncategorized

Source: CureToday articles Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me. Read More

The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma

by | Feb 8, 2025 | Myeloma News

Source: Pharmacy Times articles Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma. Read More

Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma

by | Feb 8, 2025 | Myeloma News

Source: Pharmacy Times articles The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma. Read More

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

by | Feb 7, 2025 | Publications

Hematology. 2025 Dec;30(1):2462249. doi: 10.1080/16078454.2025.2462249. Epub 2025 Feb 6. ABSTRACT BACKGROUND: The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between...
« Older Entries
Next Entries »

Recent Content

  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT